Does Insurance Cover Wegovy? 2026 Guide

Section 1: What Is Wegovy Approved For?

Wegovy (semaglutide 2.4 mg once-weekly injection) holds three FDA-approved indications:

• ✓
  Chronic weight management (obesity): As an adjunct to reduced-calorie diet and increased physical activity in adults with an initial BMI of 30 kg/m² or greater.
• ✓
  Chronic weight management (overweight with comorbidity): In adults with an initial BMI of 27 kg/m² or greater and at least one weight-related condition, such as hypertension, Type 2 diabetes, or dyslipidemia.
• ✓
  Cardiovascular risk reduction: To reduce the risk of serious cardiovascular events in adults with obesity or overweight and established cardiovascular disease (SELECT trial indication). This pathway may provide an additional coverage route on plans that restrict weight-loss coverage.

Section 2: How Coverage Is Typically Structured

Formulary tier placement

When covered, Wegovy typically appears on Tier 3 or Tier 4 (specialty tier) of commercial formularies, meaning higher cost-sharing than generic or preferred drugs. Some plans apply coinsurance (a percentage of cost) rather than a fixed copay on specialty-tier drugs, which can result in significant out-of-pocket exposure before and after the deductible. Formularies can change mid-year — check your current plan documents rather than relying on prior-year information.

Prior authorization criteria

Prior authorization is required under virtually every plan that covers Wegovy. Standard documentation requirements include:

• Current BMI documentation (BMI ≥ 30, or BMI ≥ 27 with documented comorbidity)
• Medical history and weight history demonstrating chronic obesity
• Documentation of prior lifestyle intervention (diet, exercise program) — typically 3 to 6 months
• Lab results and current medications list
• A letter of medical necessity from the prescribing physician
• For cardiovascular indication: documentation of established cardiovascular disease

PA decisions typically take 3 to 14 business days. Reauthorization is commonly required every 6 or 12 months, and may require documentation of clinical progress (weight loss and/or comorbidity improvement).

Step therapy

Some plans require step therapy before approving Wegovy. For weight management, this may mean documented use of behavioral weight-loss programs or trial of other weight-loss medications such as orlistat or phentermine-topiramate. The specific requirements vary considerably by plan. Plans that apply Cigna's utilization management, for example, have tightened step therapy requirements for GLP-1 medications specifically.

Section 3: Typical Out-of-Pocket Cost with Insurance

The list price for Wegovy is approximately $1,350 per month before insurance. Your actual cost depends on your plan's coverage and cost-sharing structure:

Section 4: Common Reasons for Denial and How to Appeal

Common denial reasons

• 1
  Plan exclusion: Your plan explicitly excludes weight-loss medications. This is now common among many employer-sponsored plans and some BCBS affiliates in 2026. An appeal arguing future medical cost savings may help in some cases.
• 2
  BMI or comorbidity criteria not met: Documentation did not clearly establish BMI ≥ 30, or BMI ≥ 27 with a qualifying comorbidity. Explicit ICD-10 codes for comorbidities must appear in clinical records.
• 3
  No prior lifestyle intervention documented: Insurer requires evidence of supervised diet or exercise program (often 3–6 months) before approving GLP-1 therapy for weight management.
• 4
  Medical necessity determination: Insurer's automated review flagged the claim as not medically necessary without reviewing clinical context. A peer-to-peer review between your doctor and the insurer's medical director can often resolve this.
• 5
  Incomplete PA documentation: Missing forms, unsigned documents, or absent supporting records. Resubmitting with a complete packet addresses this denial type.

How to appeal

1. Request your denial letter and Explanation of Benefits in writing.
2. Identify the specific denial code — medical necessity, plan exclusion, or missing documentation.
3. Work with your prescriber on a detailed letter of medical necessity that addresses the denial reason.
4. Include BMI documentation, comorbidity diagnosis codes, cardiovascular risk factors, and prior weight-loss attempt records.
5. For plan exclusion denials, consider requesting coverage under the cardiovascular risk reduction indication if you have documented cardiovascular disease (SELECT trial data supports 20% reduction in major adverse cardiovascular events).
6. Submit your appeal within 180 days of the denial notice (check your plan's specific deadline).

Novo Nordisk provides sample appeal letter templates and a Wegovy exceptions and denials guide through the NovoMedLink program at novomedlink.com. Initial denial rates for Wegovy run approximately 35–45%, but appeals with strong clinical documentation succeed in a significant portion of cases.

Section 5: Novo Nordisk Savings Programs for Wegovy

Novo Nordisk operates savings programs that can substantially reduce Wegovy costs for eligible patients:

Section 6: If Your Insurance Does Not Cover Wegovy

If coverage is denied or your plan excludes weight-loss medications, telehealth providers offer GLP-1 access with transparent pricing and licensed prescribers who ship directly to your home.

Advertising disclosure: The telehealth options below are paid sponsors. We may earn a commission when you sign up. This does not affect your pricing. Listing order does not imply medical recommendation. Always consult a licensed healthcare provider.

Section 7: Frequently Asked Questions